Ratings Carl Zeiss Meditec AG Wiener Boerse

Equities

AFX

DE0005313704

End-of-day quote Wiener Boerse Other stock markets 18:00:00 2024-06-18 EDT			5-day change	1st Jan Change
65.9 ^EUR	-0.90%		-21.59%	-33.16%

06-24	RBC lowers target for Carl Zeiss Meditec to 85 euros - 'Outperform'	DP
06-24	UBS lowers Carl Zeiss Meditec to 'Neutral' - target to 71 euros	DP

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
With an expected P/E ratio at 30.03 and 22.62 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Revenue estimates are regularly revised downwards for the current and coming years.
For the last few months, analysts have been revising downwards their earnings forecast.
Over the past four months, analysts' average price target has been revised downwards significantly.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
CARL ZEISS MEDITEC AG	-33.16%	6.41B	-
THERMO FISHER SCIENTIFIC	+4.85%	216B	B
DANAHER CORPORATION	+9.86%	190B	B-
INTUITIVE SURGICAL, INC.	+31.11%	152B	B-
BOSTON SCIENTIFIC CORPORATION	+34.08%	113B	A-
SIEMENS HEALTHINEERS AG	+1.90%	64.04B	A-
EDWARDS LIFESCIENCES CORPORATION	+19.45%	54.34B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+1.63%	49.21B	B+
AGILENT TECHNOLOGIES, INC.	-3.12%	39.41B	A
GE HEALTHCARE TECHNOLOGIES INC.	+1.93%	35.99B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes